Trinity Biotech (TRIB) Liabilities from Discontinued Operations (2016 - 2024)

Trinity Biotech (TRIB) posted quarterly Liabilities from Discontinued Operations of 800000.0 for Q4 2024, down 153.33% year-on-year from 1500000.0 in Q1 2024, and down 153.33% on a QoQ basis from 1500000.0 in Q4 2023.

Trinity Biotech (TRIB) Liabilities from Discontinued Operations (2016 - 2024) Analysis & Trends

Trinity Biotech (TRIB) has reported Liabilities from Discontinued Operations for 3 consecutive years, with 800000.0 the latest figure, recorded in Q4 2024.

  • Quarterly Liabilities from Discontinued Operations fell 153.33% year-over-year to 800000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 800000.0 (down 153.33% YoY) and the FY2024 annual result came in at 800000.0, down 153.33% from the prior year.
  • Liabilities from Discontinued Operations fell to 800000.0 in Q4 2024 per TRIB's latest filing, from 1500000.0 in the prior quarter.
  • Over the last five years, Liabilities from Discontinued Operations for TRIB reached as high as 1500000.0 in Q4 2023 and fell as low as 800000.0 in Q4 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn
9 Smith & Nephew 25.80 Bn 25.22 Bn -
10 Trinity Biotech 93,750.00 -5.04 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2024 -800,000.00
Dec 31, 2024 -800,000.00
Dec 31, 2023 1.50 Mn
Dec 31, 2023 1.50 Mn
Mar 31, 2023 1.39 Mn
Mar 31, 2023 1.39 Mn
Dec 31, 2016 3.43 Mn
Dec 31, 2016 3.43 Mn